Developing a clinical performance measures system for hemodialysis, quality group, Spanish Society of Nephrology;Desarrollo de un sistema de monitorización clínica para hemodiálisis: Propuesta de indicadores del Grupo de Gestión de Calidad de la SEN

Nefrologia

Volumn 27, Issue 5, 2007, Pages 542-559

  López Revuelta, Katia ^a   Barril, G ^b   Caramelo, C ^b   Delgado, R ^b   Garcia Lopez F ^b   Garcia Valdecasas J ^b   Gruss, E ^b   Jimenez Almonacid P ^b   Martinez Castelao A ^b   Luis Miguel, J ^b   Ortiz, A ^b   Del Pino Y Pino, Ma D ^b   Portoles J Ma ^b   Prados, C ^b   Sanz, P ^b   Tato, A ^b   Alvarez Ude F ^c   Angoso, M ^c   Aranaz, J ^c   Arenas, M D ^c   Lorenzo, S ^c   more..

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b Grupo de Expertos SEN

^c Grupo de Gestión de Calidad SEN

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY; SPAIN; STANDARD;

HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RENAL DIALYSIS; SPAIN;

EID: 39849099897     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. http://www.senefro.org/ (consultado 14/04/2007).
2. http://www.kidney.org/professionals/kdoqi/ (consultado 14/04/2007).
3. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW: Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14 (12): 3270-7, 2003.
4. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ: Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19 (1): 121-132, 2004.
5. Hecking E, Bragg-Gresham JL, Rayner HC, Pisoni RL, Andreucci VE, Combe C, Greenwood R, McCullough K, Feldman HI, Young EW, Held PJ, Port FK: Haemodialysis prescription, adherence and nutritional indicators in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19 (1): 100-107, 2004.
6. Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, Wolfe RA, Goodkin DA, Held PJ: Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int 61 (1): 305-16, 2002.
7. López Revuelta K: Monitorización del proceso de Hemodiálisis crónica. Grupo de Calidad de la SEN. Simposio: «Calidad en diálisis», XXXIV Congreso Nacional de la Sociedad Española de Nefrología, Tenerife, 2-5 de octubre de 2004. http://www.pulso.com/congresosen2004/ (consultado 14/04/2007).
8. Arenas MD, Álvarez-Ude F, Egea JJ, Gill MT, Amoedo ML, Millán I, Soriano A, Sirvent AE: Impacto del seguimiento de indicadores de calidad en hemodiálisis. Nefrología 24 (3): 261-75, 2004.
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383, 1987.
10. Bedhu S, Bruns FJ, Saul M, Seddon P, Zeidel ML: A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med 108: 609-613, 2000.
11. ESRD Special Project: Developing Clinical Performance Measures for de Care of Patients with End-Stage Renal Disease. http://www.cms.hhs.gov/CPMProject (consultado 31/01/2007).
12. Joint Comisión on Acreditation of Healthcare Organizations: Características de los indicadores clínicos. Control de Calidad Asistencial 6: 65-74, 1991.
13. Comité permanente de los hospitales de la Unión Europea: La calidad de la atención hospitalaria. Seminario europeo del programa HOPE. Limerick (Irlanda). Junio de 1997.
14. Maduell F, García M, Alcázar R: Dosificación y Adecuación del tratamiento dialítico. En Guías de centros de hemodiálisis de la SEN. Nefrología 26 (8): 15-21, 2006.
15. Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 4: 1205-1213, 1993.
16. The EBPG Expert Group on Heamodialysis: European Best Practice Guidelines for Hemaodialysis (part 1). Nephrol Dial Transplant 17 (Supl. 7), 2002.
17. K/DOQI: Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 48 (Supl. 1): S2-90, 2006.
18. http://www.cms.hhs.gov/CPMProject/Downloads/AnnualReport05final.pdf (consultado el 14/04/2007).
19. K/DOQI: Clinical practice guidelines for vascular access. Am J Kidney Dis 48 (Supl. 1): S176-247, 2006.
20. Rodríguez Hernández JA, López Peret J, Piera L: El acceso vascular en España: análisis de su distribución, morbilidad y sistemas de monitorización. Nefrología 21: 45-51, 2001.
21. aT, Arrieta J, Fernández Rivera C, Galera A, Gallego Beuter J, Górriz JL, Herrero JA, López Menchero R, Ochando A, Pérez Bañasco V, Polo JR, Pueyo J, Ruiz Camps I, Segura Iglesias R: Guías de acceso vascular en Hemodiálisis. Nefrología 25 (S1), 2005.
22. Armada E, Trillo M, Pérez Melón C, Molina Herrero J, Ganoso P, Camba M, Esteban Morcillo J, Otero A: Programa de monitorización de accesos vasculares nativos para hemodiálisis. Nefrología 25 (1): 57-66, 2005.
23. K/DOQI: Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Guideline 3. Am J Kidney Dis 42 (Supl. 3), 2003.
24. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port F, Koung E: Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 67 (3): 1179-87, 2005.
25. Díaz Corte C, Naves ML, Rodríguez A, Barreto S, Gómez C, Cannata J, centros colaboradores: Osteodistrofia renal en España. Encuesta multicéntrica (I). Nefrología 20 (3): 234-243, 2000.
26. Elder G, Faull R, Branley P y cols.: The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone. Nephrology (Carlton) 11 (Supl. 1): S230-261, 2006.
27. Wei M, Taskapan H, Esbaei K, Jassal SV, Bargman JM, Oreopoulos: K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them? Int Urol Nephrol 38 (3-4): 739-743, 2006.
28. Shahapuni I, Mansour J, Harbouche L y cols.: How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Semin Dial 18: 226-238, 2005.
29. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G: Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953, 2006. 〈http://www. nature.com/ki/journal/v69/n11/full/5000414a.html
30. KDOQI: Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 (Supl. 3): s11-145, 2006.
31. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrology Dialysis Transplantation 19 (Supl. 2): ii6-ii15, 2004.
32. Phrommintikul A, Haas SJ, Elsik M, Krum H: Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369 (9559): 381-388, 2007.
33. Pérez García R: Estudio Colaborativo Español: Spanish survey on anaemia management. Nefrología 23: 300-311, 2003.
34. Portolés J, López-Gómez JM, Aljama P: Anemia management and treatment response in patients on hemodialysis: the MAR study. J Nephrol 19 (3): 352-60, 2006.
35. Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F (en representación del grupo de estudio NESP 20000114): Estudio Darbe Español: estudio multicéntrico de darbepoetin alfa en el tratamiento de la anemia secundaria a insuficiencia renal crónica en diálisis. Nefrología 23: 114-125, 2003.
36. Easom A: The challenges of using serum ferritin to guide iv iron treatment practices in patients on hemodialysis with anemia. Nephrol Nurs J 33: 543-551; quiz 552-543, 2006.
37. Kalantar-Zadeh K, Rodríguez RA, Humphreys MH: Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 19: 141-149, 2004.
38. Barril G, González E, Espinosa M, Caramelo C, García Valdecasas J, Arenas MD, Górriz JL, Campistol JM, Alcázar R, Teruel JL, López MD, Ruiz P, Martín L, Carreño V, Carrasco M: Guías sobre enfermedades víricas en hemodiálisis. Nefrología 24: 43-66, 2004.
39. Pérez García,R, González E, Ceballos F, Escallada R, Gómez-Reino MI, Martín-Rabadán P, Pérez García A, Ramírez R, Sobrino PE, Solozábal C: Guías de gestión de calidad del líquido de hemodiálisis. Nefrología 24: 1-42, 2004.
40. Cannata JB: Tratamiento de la intoxicación alumínica: limitaciones de los estudios sobre movilización de aluminio. Nefrología 13 (Supl. 3): 119-122, 1993.
41. Greene T, Daugirdas J, Beck G, Depner T, Ornt D, Schulman G, Star R, Eknoyan G, and the HEMO Study: Statistical basis for performance standards for achieving a minimum spKt/V goal based on variability observed in the NIH HEMO Study. Proceedings of the XVth International Congress of Nephrology, Buenos Aires, Argentina, pp. 419, 1999.
42. Kannel WB, McGee D, Gordon T: A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 38: 46-51, 1976.
43. Agarwal R: Systolic hypertension in hemodialysis patients. Semin Dial 16 (3): 208-13, 2003.
44. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560-2572, 2003.
45. Port FK, Hulbert-Shearon TE y cols.: «Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients». Am J Kidney Dis 33 (3): 507-17, 1999.
46. Schomig M, Eisenhardt A, Ritz E: Controversy on optimal blood pressure on haemodialysis: normotensive blood pressure values are essential for survival. Nephrol Dial Transplant 16 (3): 469-74, 2001.
47. K/DOQI: Clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 41 (Supl. 3): I-IV, S1-91, 2003.
48. Viola RA, Abbott KC, Welch PG, McMillan RJ, Sheikh AM, Yuan CM: A multidisciplinary program for achieving lipid goals in chronic hemodialysis patients. BMC Nephrol 3: 9-16, 2002.
49. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005.
50. Kimmel PL, Varela MP, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Amarashinge A, Mishkin GJ, Cruz, I, Veis JH: Interdialytic weight gain and survival in hemodialysis patients: effects of duration of ESRD and diabetes mellitus. Kidney Int 57 (3): 1141-51, 2000.
51. Leggat JE, Orzol SM, Hulbert-Shearon TE, Golper TA, Jones CA, Held PJ, Port FK: Noncompliance in hemodialysis: predictors and survival analysis. Am J Kidney Dis 32 (1): 139-45, 1998.
52. Gruss E, Caramelo C, Fernández J, Martínez S, Gago C, Marco B, Hernando P, Gómez J, Molins A: ¿Por qué acuden los pacientes de hemodiálisis extrahospitalaria a los servicios de urgencia hospitalarios? Nefrología 20 (4): 336-341, 2000.
53. Carrera F, Oliveira L, Maia P y cols.: The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant 21: 2846-2850, 2006.
54. Priyadarshi A, Shapiro JI: Erythropoietin resistance in the treatment of the anemia of chronic renal failure. Semin Dial 19: 273-278, 2006.
55. Collins AJ, Brenner RM, Offman JJ: Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 46: 481-488, 2005.
56. Dirección general de salud pública. Ministerio de Sanidad y Consumo. Enfermedades y lesiones. La gripe. Publicado 14/11/2003.
57. Castillo I, Pardo M, Bartolomé J, Ortiz-Movilla N, Rodríguez E, de Lucas S, Salas C, Jiménez-Heffernan JA, Pérez-Mota A, Graus J, López-Alcorocho JM, Carreño V: Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 189 (1): 7-14, 2004.
58. Rettig RA, Sadler JH, Meyer KB, Wasson JH, Parkerson GR, Kantz B, Hays RD, Patrick DL: Assessing health and quality of life outcomes in dialysis: a report on an Institute of Medicine workshop. Am J Kidney Dis 30 (1): 140-155, 1997.
59. López Revuelta K, García López FJ, De Álvaro Moreno F, Alonso J: Perceived mental health at the start of dialysis as a predictor of morbidity and mortality in patients with end-stage renal disease. Nephrol Dial Transplant 19 (9): 2347-2353, 2004.
60. Ware JE, Sherbourne CD. The MOS 36-Item Short Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 30: 473-483, 1992.
61. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary test of reliability and validity. Med Care 34 (3): 220-233, 1996.
62. Rocco MV, Frankenfield, MV, Hopson SD, McClellan, VM: Relationship between Clinical Performance Measures and Outcomes among Patients Receiving Long-Term Hemodialysis. Ann Intern Med 145: 512-519, 2006.
63. Plantinga LC, Fink NE, Jaar BG, Sadler JH, Levin NW, Coresh J, Klag MJ, Powe NR: Attainment of clinical performance targets and improvement in clinical outcomes and resource use in hemodialysis care: a prospective cohort study. BMC Health Services Research 7: 5-18, 2007.